Neurocentria

Biotechnology, 1855 Olympic BLVD Ste 225, Walnut Creek, California, 94596, United States, 11-50 Employees

Phone Number: 92********

Who is NEUROCENTRIA

Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depressio...

Get Full Access

Headquarters: 1855 Olympic BLVD Ste 225, Walnut Creek, California, 94596, United States
Date Founded: 2005
Employees: 11-50
Revenue: $1 Million to $5 Million
Active Tech Stack: See technologies
CEO: Guosong Liu
- Email
- Phone

Industry: Biotechnology

SIC Code: 2834

Does something look wrong? Fix it. | View contact records from NEUROCENTRIA

Neurocentria Org Chart and Mapping

Inc. Neurocentria

Human Resources Executive

Email
Phone

See Full Org Chart

Similar Companies to Neurocentria

Eikon Therapeutics

201-500
$ 10 Million to 25 Million

View all Neurocentria competitors

View Email Formats for Neurocentria

You are signed out

Join Now

Free credits every month

Frequently Asked Questions Regarding Neurocentria

Answer: Neurocentria's headquarters are located at 1855 Olympic BLVD Ste 225, Walnut Creek, California, 94596, United States

Answer: Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depression and Alzheimers disease. Since 2005, our team has been innovating breakthrough therapies to address the pathophysiology of these disorders, prevent their progression or even reverse their course, reduce symptoms and improve patients performance and quality of life. Currently available treatments for these disorders are acting on classical targets identified decades ago, especially for ADHD and depression, with no new approaches introduced during this time. And, too often, patients endure just as much from the side effects of their medications. Our novel therapy, NRCT-101SR, is a new class of treatment for neurological disorders, developed to act on new molecular targets. In preclinical studies, NRCT-101, the API of NRCT-101SR, increased synapse density and plasticity, improving synaptic function. Importantly, NRCT-101 enhanced cognitive function and improved emotional regulation in young animals, and prevented synaptic loss and alleviated cognitive impairment in aged animals. Similar effects of NRCT-101 were seen in models of neuroinflammation. In early-stage human clinical trials, NRCT-101 was shown to: Improve mood status in 3-7 days versus the several weeks it takes for most medications Address ADHD symptoms without imposing side effects Improve cognition for adults with late-life depression, anxiety, ADHD and Alzheimers & Alzheimers-like symptoms Produce no negative side effects The FDA recently approved our drug candidate for a pivotal Phase IIb/III human trial for adults with ADHD, a Phase IIb human trial in Alzheimers, and we are working on a phase IIb/III human trial in adults with major depressive disorder. We are fully committed to developing novel brain health therapies that are safe, improve peoples conditions and promote healthy communities.